Olema Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
| Accumulated | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||||||||||||
| Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||||||||||||
| Balances at March 31, 2025 | 68,333,065 | $ | 7 | $ | 848,520 | $ | 420 | $ | (465,495) | $ | 383,452 | ||||||||||
| Stock-based compensation expense, including employee stock purchase plan expense | — | — | 4,692 | — | — | 4,692 | |||||||||||||||
| Issuance of shares under employee stock purchase plan | 206,609 | — | 748 | — | — | 748 | |||||||||||||||
| Exercise of stock options | 88,212 | — | 234 | — | — | 234 | |||||||||||||||
| Net unrealized loss on marketable securities | — | — | — | (106) | — | (106) | |||||||||||||||
| Net loss | — | — | — | — | (43,784) | (43,784) | |||||||||||||||
| Balances at June 30, 2025 | 68,627,886 | $ | 7 | $ | 854,194 | $ | 314 | $ | (509,279) | $ | 345,236 | ||||||||||
| Accumulated | |||||||||||||||||||||
| Additional · Other · Total | |||||||||||||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||||||||||||
| Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||||||||||||
| Balances at December 31, 2024 | 74,312,608 | $ | 7 | $ | 843,920 | $ | 143 | $ | (435,106) | $ | 408,964 | ||||||||||
| Stock-based compensation expense, including employee stock purchase plan expense | — | — | 9,070 | — | — | 9,070 | |||||||||||||||
| Issuance of shares under employee stock purchase plan | 206,609 | — | 748 | — | — | 748 | |||||||||||||||
| Exercise of stock options | 178,669 | — | 470 | — | — | 470 | |||||||||||||||
| Issuance cost associated with private equity placement | — | — | (14) | — | — | (14) | |||||||||||||||
| Exchange of common stock shares for pre-funded warrants | (6,070,000) | — | — | — | — | — | |||||||||||||||
| Net unrealized gain on marketable securities | — | — | — | 171 | — | 171 | |||||||||||||||
| Net loss | — | — | — | — | (74,173) | (74,173) | |||||||||||||||
| Balances at June 30, 2025 | 68,627,886 | $ | 7 | $ | 854,194 | $ | 314 | $ | (509,279) | $ | 345,236 | ||||||||||
Condensed Consolidated Statements of Cash Flows
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.